ZHEJIANG POLY PHARM CO LTD
GenericsZHEJIANG POLY PHARM CO LTD is a generic drug manufacturer focused on Neurology, Infectious Disease, Respiratory.
ZHEJIANG POLY PHARM CO LTD's Key Drugs
ZHEJIANG POLY PHARM CO LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ZHEJIANG POLY PHARM CO LTD's Recent FDA Approvals
New NDA/BLA approvals for ZHEJIANG POLY PHARM CO LTD over the last two years — novel drugs only, excluding generics and label supplements.
ZHEJIANG POLY PHARM CO LTD's Therapeutic Areas
ZHEJIANG POLY PHARM CO LTD's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ZHEJIANG POLY PHARM CO LTD's Top Competitors
ZHEJIANG POLY PHARM CO LTD's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Bristol-Myers Squibb, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ZHEJIANG POLY PHARM CO LTD Pipeline Snapshot
Active clinical trials for ZHEJIANG POLY PHARM CO LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-07-27
- Latest
- 2026-02-23
- Applications
- 8